A collaborative team of interdisciplinary researchers led by Dr. Ryan P. Hobbs, PhD, a postdoctoral fellow at John Hopkins Bloomberg School of Public Health’s Department of Biochemistry and Molecular Biology, recently revealed study findings suggesting a protein known as keratin 17, a clinical biomarker for many types of cancers, may also play a significant role in tumor growth. The findings from the study, entitled, “Keratin-dependent regulation of Aire and gene expression in skin tumor keratinocytes,” were published in the latest edition of Nature Genetics.
MRV Research
Selumetinib Misses Endpoint in Phase III Uveal Melanoma Study
Treatment with the combination of selumetinib and dacarbazine failed to improve progression-free survival (PFS) compared with dacarbazine alone in patients with metastatic uveal melanoma, according to top-line findings from the phase III SUMIT trial released by AstraZeneca.
AB Science announces successful futility test for masitinib in c-Kit mutated metastatic melanoma
AB Science SA , a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), today announced the successful non futility analysis related to the masitinib phase 3 trial in metastatic melanoma, carrying a mutation in the juxta membrane domain of c-Kit. Based on these results, the Independent Data Safety Monitoring Committee (IDMC) has recommended continuation of the study.
Early SLNB may worsen melanoma-specific survival, DFS
A sentinel lymph node biopsy within 40 days of tumor excision appeared to worsen survival in patients with cutaneous melanoma compared with a delayed biopsy, according to study results.